Ion Beam Applications SA
XBRU:IBAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.34
15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ion Beam Applications SA
Ion Beam Applications SA
Cost of Revenue
Ion Beam Applications SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Cost of Revenue
-€294.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Cost of Revenue
-€1.7m
|
CAGR 3-Years
-281%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biocartis Group NV
XBRU:BCART
|
Cost of Revenue
-€29.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Cost of Revenue
-€4.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Ion Beam Applications SA
Glance View
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. The company is headquartered in Louvain-La-Neuve, Brabant-Wallon. IBA is also active in the sterilization and ionization field. The firm operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
See Also
What is Ion Beam Applications SA's Cost of Revenue?
Cost of Revenue
-294.3m
EUR
Based on the financial report for Dec 31, 2023, Ion Beam Applications SA's Cost of Revenue amounts to -294.3m EUR.
What is Ion Beam Applications SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-13%
Over the last year, the Cost of Revenue growth was -25%. The average annual Cost of Revenue growth rates for Ion Beam Applications SA have been -19% over the past three years , -13% over the past five years .
You don't have any saved screeners yet
